GlassScriptPhysician profile
John G Biggs
NPI 1992803779
$1,999.08
in general payments reported to CMS, 2019-2025
27 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $26.52 · 2021: $354 · 2022: $223 · 2023: $523 · 2024: $298 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $460.77 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $268.96 | 2020-2025 | Ubrelvy, Synthroid |
| Lilly USA, LLC | $154.96 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $136.34 | 2021-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.32 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $102.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $73.97 | 2019 | |
| Amneal Pharmaceuticals LLC | $66.51 | 2023-2024 | Unithroid |
| Glaxosmithkline, LLC. | $61.16 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $60.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $59.02 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $57.09 | 2019-2023 | |
| Inspire Medical Systems, INC. | $53.08 | 2023-2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $47.60 | 2025 | Nuzyra |
| Allergan, INC. | $41.54 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $34.40 | 2023-2025 | Wavewriter Alpha Prime 16, Watchman |
| Astellas Pharma US INC | $31.77 | 2019-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $28.66 | 2021 | |
| Sanofi Pasteur INC. | $25.18 | 2023 | |
| Abbott Laboratories | $19.28 | 2022 | |
| Medtronic, INC. | $16.93 | 2022 | |
| Tactile Systems Technology INC | $14.76 | 2025 | Nimbl, Flexitouch Plus |
| Shield Therapeutics INC | $14.47 | 2023 | Accrufer |
| Nabriva Therapeutics, Plc | $12.70 | 2021 | |
| Hikma Pharmaceuticals USA | $11.87 | 2021 | |
| Eyevance Pharmaceuticals LLC | $11.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Biggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.